Medicare told to reassess premium hike after price slashed on Biogen Alzheimer's drug

Biogen cut the annual price per patient of its controversial new Alzheimer's drug, Aduhelm, from $56,000 to $28,200

Department of Health and Human Services Secretary Xavier Becerra announced Monday that he has ordered Medicare to "reassess" the agency's 2022 premium rate hike for Medicare Part B, citing Biogen's move to slash the price of its costly new Alzheimer's drug – which was blamed for a hefty portion of the premium increase that impacts tens of millions of Americans.

Xavier Becerra

Health and Human Services Secretary Xavier Becerra speaks in the East Room of the White House in Washington, D.C., on December 1, 2021. (Photo by MANDEL NGAN/AFP via Getty Images) (Photo by MANDEL NGAN/AFP via Getty Images / Getty Images)

"Today I’m instructing the Centers for Medicare and Medicaid Services (CMS) to reassess the recommendation for the 2022 Medicare Part B premium, given the dramatic price change of the Alzheimer’s drug, Aduhelm," Becerra said in a statement. "With the 50% price drop of Aduhelm on January 1, there is a compelling basis for CMS to reexamine the previous recommendation."

A CMS spokesperson told FOX Business that the agency "is reviewing the Secretary's statement to determine next steps." 

Medicare Part B premiums, which more than 50 million Americans pay, are rising by $21.60 per month this year, which is a 14.5% boost. Roughly half that amount, $11, was blamed on the agency covering the cost of Aduhelm, a controversial new drug that Biogen originally priced at $56,000 per patient annually following the drug's approval in June.

Aduhelm biogen

This image provided by Biogen on Monday, June 7, 2021, shows a vial and packaging for the drug Aduhelm.  (Biogen via AP / AP Newsroom)

FDA TRIMS USE OF CONTENTIOUS ALZHEIMER'S DRUG AMID BACKLASH

Biogen cut the price of Aduhelm by roughly half down to $28,200 at the first of the year, acknowledging that the price tag was a barrier keeping patients from obtaining prescriptions. 

"Too many patients are not being offered the choice of Aduhelm due to financial considerations and are thus progressing beyond the point of benefiting from the first treatment to address an underlying pathology of Alzheimer’s disease," Biogen CEO Michel Vounatsos said in announcing the move, adding, "We recognize that this challenge must be addressed in a way that is perceived to be sustainable for the U.S. healthcare system."

biogen

Pedestrians walk past Biogen Inc. headquarters in Cambridge, Massachusetts (Photographer: Adam Glanzman/Bloomberg via Getty Images) ( Adam Glanzman/Bloomberg via Getty Images / Getty Images)

Ticker Security Last Change Change %
BIIB BIOGEN INC. 230.81 -3.00 -1.28%

GET FOX BUSINESS ON THE GO BY CLICKING HERE

A Biogen spokesperson told FOX Business on Monday, "We welcome HHS Secretary Becerra's announcement to re-evaluate the Medicare premium increase for 2022 given that we announced in December a reduced price for Aduhelm and provided greater clarity around what we believe the patient population for 2022 would look like with insurance coverage and access to diagnostics and specialized centers."

Critics faulted the Food and Drug Administration for approving Aduhelm last summer not only due the drug's eye-popping cost, but also due to ongoing questions over its effectiveness. Three outside advisors to the FDA resigned over the agency's approval of the drug, with one of them saying it was "the worst drug approval decision in recent history."

The Associated Press contributed to this report.